Pharmafile Logo
Pharmafocus logo
Advanced Search

Eisai

Showing 15 posts of 110 posts found.

Alzheimer's brain

FDA grants Alzheimer’s disease drug Leqembi full approval

July 7, 2023
Medical Communications Alzheimer's disease, Biogen, Eisai, FDA, Neurology

Japanese pharmaceutical company Eisai and US-based biotechnology company Biogen have announced that the US Food and Drug Administration (FDA) has …

News
shutterstock_273326141

Eisai and Wren Therapeutics join forces to tackle neurodegenerative synucleinopathies

December 1, 2020
Manufacturing and Production, Research and Development, Sales and Marketing Eisai, Wren Therapeutics

Eisai has forged an exclusive research partnership with Wren Therapeutics to develop new approaches in tackling neurodegenerative diseases known as …

News
shutter

Japan approves Gilead and Eisai’s Jyseleca for rheumatoid arthritis

September 25, 2020
Medical Communications, Sales and Marketing Eisai, Gilead, Japan, Jyseleca

Gilead and Eisai have secured approval for their oral JAK1 preferential inhibitor Jyseleca (filgotinib) from the Japanese Ministry of Health, …

News
shutterstock_38078521

New Lenvima/Keytruda combo data in a range of cancers presented at ESMO 2020

September 21, 2020
Research and Development, Sales and Marketing Cancer, ESMO2020, Eisai, Lenvima, MSD, keytruda

New data from two studies investigating the combination of Eisai’s multiple receptor tyrosine kinase inhibitor Lenvima (lenvatinib) and MSD’s blockbuster …

News
eisa0008_web

Eisai releases new Phase 2 data for levatinib+everolimus combo in advanced kidney cancer

February 17, 2020
Research and Development, Sales and Marketing Cancer, Eisai, Kidney cancer, Lenvima, pharma, renal cell carcinoma

New Phase 2 data has been revealed for Eisai’s Lenvima (levatinib), delivered alongside Novartis’ everolimus, for the treatment of unresectable …

News
eisa0008_web

Eisai withdraws weight loss drug Belviq after FDA highlights cancer risk

February 14, 2020
Medical Communications, Research and Development, Sales and Marketing Belviq, Eisai, FDA, pharma

The FDA has requested that Eisai withdraw its weight loss drug Belviq (lorcaserin) and Belviq XR from the US market …

News
eisa0008_web

Scottish Medicines Consortium recommends Eisai’s Kisplyx for advanced kidney cancer

November 12, 2019
Manufacturing and Production, Sales and Marketing Eisai, Kisplyx, NHS, Sotland, pharma

Eisai’s Kisplyx (lenvatinib) has secured recommendation from the Scottish Medicines Consortium, it has been revealed, meaning that patients on the …

News
eisa0008_web

China approves Eisai’s Fycompa for partial onset epileptic seizures

October 16, 2019
Research and Development, Sales and Marketing China, Eisai, Fycompa, epilepsy, pharma

Tokyo-headquartered firm Eisai has announced that its antiepileptic drug (AED) Fycompa (perampanel) has received approval from China’s National Medical Products …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

April 12, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, BMS, Eisai, Gilead, MSD, Pfizer, ViiV, indivior

This week was an excellent week for recommendations and approvals after Eisai, MSD, Pfizer, BMS and ViiV scored wins. Meanwhile …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

March 22, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Biogen, Eisai, FDA, Merck, NICE, Pfizer, Roche, Sandoz

This week was a bad week for clinical trials. While the FDA put Roche and AbbVie’s multiple myeloma trial on …

News
eisa0008_web

Biogen and Eisai discontinue Phase 3 Alzheimer’s trial

March 21, 2019
Research and Development Alzheimer's, Biogen, CNS, Eisai, mental health

Biogen and Eisai have announced their decision to discontinue a Phase 3 trial looking into the efficacy and safety of …

News
shutterstock_360472550

Eisai and Purdue reveal positive Phase 3 data in insomnia

February 7, 2019
Research and Development Eisai, Purdue Pharma, insomnia, lemborexant, pharma

Partners Eisai and Purdue Pharma have lifted the curtain on Phase 3 clinical data on their jointly developed therapy lemborexant …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

December 21, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Eisai, Eli Lilly, Novartis, Teva, Tilray, brexit, celltrion, pharma, top 10

Deals dominated this week as GSK and Pfizer announced that they would combine their consumer healthcare units in a collaboration …

News
82958bfc7df1311fd17a008495fc-1456375

Pharma in 2018: Looking back, looking forward

December 18, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2018, Alligator Bioscience, Eisai, Gilead, Mundipharma, pharma

2018 has been a year characterised by uncertainty, but also significant leaps in research, access, and industry deals. With 2019 …

Feature
pharmafocus_dec_2018_cover

The December issue of Pharmafocus is available to read online now!

December 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eisai, GSK, Gilead, Mundipharma, Pharmafocus, mesothelioma, pharma

The December edition of Pharmafocus is live and available to read online now!Brexit continues to dominate the headlines inside and …

News

Latest content

Novo Nordisk partners with UNICEF to prevent global childhood obesity

September 21, 2023

EC approves Menarini Group’s Orserdu for breast cancer treatment

September 21, 2023

Pharmanovia acquires CNS portfolio from Sanofi

September 20, 2023

Exscientia enters AI drug discovery collaboration with Merck KGaA

September 20, 2023

EC approves Pfizer’s Litfulo for adolescents and adults with alopecia

September 19, 2023